KIT and hepatocellular carcinoma: In the past decade, sorafenib, multi-kinase inhibitor [against vascular endothelial growth factor receptor (VEGFR)1-3, fms-like tyrosine kinase 3, RET and RAF kinases, platelet-derived growth factor (PDGF) and KIT], has crucially contributed to the systemic therapy of patients with advanced or metastatic hepatocellular carcinoma (HCC) or clear cell carcinoma of the kidney 3, 4.